Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
Patrick J Haley sold 126,383 shares of EXEL on 15 May at $48.05 per share, worth a total of $6.1M. They now own 446,459 EXEL shares, or a 22% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
